Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 — China, 2020

Modeling the Prediction on the Efficacy of a Homologous Third Dose of CoronaVac Against SARS-CoV-2 Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 — China, 2020–2021

Published:2023 Issue:5 Volume:5 Page:103-107
ISSN:2096-7071
Container-title:China CDC Weekly
language:en
Short-container-title:

Author:

Chen Xinhua, ,Bai Xufang,Chen Xinghui,Zheng Nan,Yang Juan,Zhang Juanjuan,Yu Hongjie, ,

Publisher

Chinese Center for Disease Control and Prevention

Subject

Public Health, Environmental and Occupational Health,Infectious Diseases,Epidemiology

Link

https://weekly.chinacdc.cn/en/article/pdf/preview/10.46234/ccdcw2023.019

Reference19 articles.

1. WHO. Tracking SARS-CoV-2 variants. 2021. https://www.who.int/activities/tracking-SARS-CoV-2-variants/. [2022-9-15].

2. Gangavarapu K, Latif AA, Mullen JL, Alkuzweny M, Hufbauer E, Tsueng G, et al. Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. medRxiv 2022. http://dx.doi.org/10.1101/2022.01.27.22269965.

3. Xin QQ, Wu QH, Chen XH, Han BH, Chu K, Song Y, et al. Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nat Commun 2022;13(1):3100. http://dx.doi.org/10.1038/s41467-022-30864-w.

4. Cheng SSM, Mok CKP, Li JKC, Ng SS, Lam BHS, Jeevan T, et al. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection. J Clin Virol 2022;156:105273. http://dx.doi.org/10.1016/j.jcv.2022.105273.

5. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021;27(7):1205-11. http://dx.doi.org/10.1038/S41591-021-01377-8.